Pfizer Receives ₹85.74 Crore Income Tax Assessment Order and Penalty Notice
Pfizer has received an Income Tax Assessment Order demanding ₹85,73,96,440 for FY2022-23 along with a penalty notice. The company plans to appeal and expects no material impact on its financial position or operations.
*this image is generated using AI for illustrative purposes only.
Pfizer has received an Assessment Order from the Income Tax Department demanding ₹85,73,96,440 along with a show-cause notice for penalty proceedings. The pharmaceutical company disclosed this development through a regulatory filing under SEBI Listing Regulations, providing detailed information about the tax assessment for Financial Year 2022-23.
Assessment Order Details
| Parameter | Details |
|---|---|
| Tax Demand Amount | ₹85,73,96,440 (Rupees Eighty Five Crore Seventy Three Lakhs Ninety Six Thousand Four Hundred Forty only) |
| Order Date | April 23, 2026 |
| Assessment Period | Financial Year 2022-23 |
| Issuing Authority | Income Tax Department – Assessment Unit |
| Legal Sections | 143(3) read with 144C(3) & 144B of Income Tax Act, 1961 |
Nature of Tax Dispute
The Income Tax Department has raised the demand citing alleged under-reporting of income due to disallowance of expenses in the tax return filed for FY2022-23. Additionally, the department has issued a show-cause notice for initiating penalty proceedings under sections 274 read with 270A of the Income Tax Act, 1961.
Company's Response Strategy
Pfizer is currently evaluating the Assessment Order and plans to take appropriate legal steps within prescribed timelines. The company intends to file an appeal and/or application for stay against the order. Based on preliminary factual and legal assessment, Pfizer believes it has strong grounds on merits to contest the tax department's claims.
Financial Impact Assessment
| Impact Area | Company Position |
|---|---|
| Financial Position | No material impact expected |
| Operations | No disruption anticipated |
| Legal Defence | Strong grounds on merits |
| Next Steps | Appeal and stay application planned |
The company has stated that it does not expect the Assessment Order to have any material impact on its financial position, operations, or other activities at this stage. This assessment reflects Pfizer's confidence in successfully defending against the Income Tax Department's allegations through the appropriate legal channels available under the tax laws.
Historical Stock Returns for Pfizer
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.10% | -1.12% | +0.40% | -10.61% | +10.36% | -11.26% |
How might this tax dispute affect Pfizer's future investment plans and expansion strategies in the Indian pharmaceutical market?
Could this assessment order signal increased scrutiny from Indian tax authorities on other multinational pharmaceutical companies' expense reporting practices?
What impact could a prolonged legal battle have on Pfizer's quarterly earnings and stock performance over the next 12-18 months?
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
